Synergistic, and the SOC in studies often includes other treatments.Ġ 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Sotrovimab 89% 0.11 1 $2,100 1,057 intravenous Cost Studies Patients Improvement, RR Vitamin D 86% 0.14 5 $1 526 few trials/events Nigella Sativa 84% 0.16 3 $5 915 few trials/events Paxlovid 83% 0.17 2 $700 2,939 very few trials/events Budesonide 82% 0.18 1 $4 146 very few trials/events Bromhexine 79% 0.21 2 $5 96 very few trials/events Vitamin A 79% 0.21 2 $2 240 very few trials/events Quercetin 79% 0.21 2 $5 194 very few trials/events Bamlanivimab 79% 0.21 6 $1,250 17,653 high variant dependence Melatonin 78% 0.22 2 $1 91 very few trials/events Zinc 74% 0.26 3 $1 982 very few trials/events Proxalutamide 73% 0.27 2 n/a 445 very few trials/events Curcumin 71% 0.29 6 $5 707 few trials/events Povidone-Iod. Protocols typically combine multiple treatments which may be complementary and Please see the specific stage and outcome Stages and outcomes tested - for example late stage treatment may be lessĮffective and if the majority of studies are late stage this may obscure theĮfficacy of early treatment. Pooled results across all stages and outcomes depend on the distribution of Plasma -1% 1.01 14 $5,000 15,607 intravenous All studies combined (pooled effects, all stages) Favors treatment Favors controlĪll studies combined (pooled effects, all stages). 80% 0.20 1 $1 394 very few trials/events Casirivimab/i. Recently added: Hydroxychloro.: McKinnon Povidone-Iod.: Pelletier Vitamin D: Chiodini Sotrovimab: Rockett Casirivimab/i.: Suzuki (more.). Denying efficacy increases the risk of COVID-19īecoming endemic and increases mortality, morbidity, and collateralĭamage. No treatment, vaccine, or intervention is 100% available andĮffective for all variants.
Elimination is a race against viralĮvolution. All practical,Įffective, and safe means should be used. Treatments do not replace vaccines and other measures. Be sure to check the copyright laws for your country before downloading, reading or sharing this file.Analysis of 30 COVID-19 early treatments, and database ofĦ8 countries have approved early treatments. This book was published in Australia and is out of copyright there.
0 kommentar(er)
